The Clinical Phenotype of Succinic Semialdehyde Dehydrogenase Deficiency (4-Hydroxybutyric Aciduria): Case Reports of 23 New Patients

K. Michael Gibson, PhD*; Ernst Christensen, PhD†; Cornelis Jacobs, PhD§; Brian Fowler, PhD∥; Michael A. Clarke, MD¶; Gerhard Hammersen, MD;; Klaus Raab, MD#; Joyce Kobori, MD**; Allie Moosa, MD††; Brigitte Volmer, MD‡‡; Eva Rossier, MD¶¶; A. Kimberly Iafolla, MD†††; Dietrich Matern, MD##; Oebele F. Brouwer, MD***; Janice Finkelstein, MD††††; Fuat Aksu, MD‡‡‡; Hans-Peter Weber, MD¶¶¶; Jan A. J. M. Bakkeren, PhD††††; Fons J. M. Gabreels, MD†††††; Daniel Bluestone, MD‡‡‡‡; Todd F. Barron, MD*****; Pierre Beauvais, MD‡‡‡‡‡; Daniel Rabier, PhD‡‡‡‡‡‡; Cesar Santos, MD¶¶¶¶; Richard Umanovsky, MD††††††; and Willy Lehnhert, PhD‡‡‡‡‡‡‡

ABSTRACT. Objectives. To further define the clinical spectrum of the disease for pediatric and metabolic specialists, and to suggest that the general pediatrician and pediatric neurologist consider succinic semialdehyde dehydrogenase (SSADH) deficiency in the differential diagnosis of patients with (idiopathic) mental retardation and to emphasize the need for accurate, quantitative organic acid analysis in such patients.

Patients. The clinical features of 23 patients (20 families) with SSADH deficiency (4-hydroxybutyric aciduria) are presented. The age at diagnosis ranged from 3 months to 25 years in the 11 male and 12 female patients; consanguinity was noted in 39% of families.

Outcome Measurements. The following abnormalities were observed (frequency in 23 patients): motor delay, including fine-motor skills, 78%; language delay, 78%; hypotonia, 74%; mental delay, 74%; seizures, 48%; decreased or absent reflexes, 39%; ataxia, 30%; behavioral problems, 30%; hyperkinesis, 30%; neonatal problems, 26%; and electroencephalographic abnormalities, 26%. Associated findings included psychoses, cranial magnetic resonance or computed tomographic abnormalities, and ocular problems in 22% or less of patients. Therapy with vigabatrin proved beneficial to varying degrees in 35% of the patients. Normal early development was noted in 30% of patients.

Conclusions. Our data imply that two groups of patients with SSADH deficiency exist, differentiated by the course of early development. Our recommendation would be that accurate, quantitative organic acid analysis in an appropriate specialist laboratory be requested for any patients presenting with two or more features of mental, motor, or language delay and hypotonia of unknown cause. Such analyses are the only definitive way to diagnose SSADH deficiency; the diagnosis can be confirmed by determination of enzyme activity in white cells from whole blood. We think that increased use of organic acid determination will lead to increased diagnosis of SSADH deficiency and a more accurate representation of disease frequency. As additional patients are identified, we should have a better understanding of both the metabolic and clinical profiles of SSADH deficiency.

Pediatrics 1997;99:567-574; mental retardation, succinic semialdehyde dehydrogenase deficiency, 4-hydroxybutyric aciduria, hypotonia, ataxia.

ABBREVIATIONS. SSADH, succinic semialdehyde dehydrogenase; GABA, γ-aminobutyric acid; MRI, magnetic resonance imaging; EEG, electroencephalogram; CT, computed tomography; EMG, electroneuromyography.

Succinic semialdehyde dehydrogenase (SSADH, EC 1.2.1.24) deficiency (4-hydroxybutyric aciduria, McKusick 271980) is a rare inherited defect in the degradative pathway of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).1 Approximately 40 patients have been reported, with a wide variability in clinical phenotype.2 This disorder is unusual because it is a defect of neurotransmitter metabolism.
as well as one in which the accumulated diagnostic metabolite, 4-hydroxybutyric acid, also has unique neuropharmacologic properties (Table). Most patients show some degree of retardation in psychomotor and language development, often associated with hypotonia and/or ataxia. The difficulty lies in detection, because the disorder presents with such non-specific neurologic features that most neurologic or metabolic specialists are unlikely to request organic acid quantification. Without such analyses, these patients remain undiagnosed. Some of the patients we studied were initially examined for cerebral palsy or fragile X syndrome. Our review of these patients led us to suggest the existence of two distinct groups of SSADH-deficient patients, those with normal early development and others with developmental problems during infancy.

**METHODS**

Urinary organic acid analysis identified increased excretion of 4-hydroxybutyric acid in all patients (except P.S.H., who died at 13 years of age and whose diagnosis was deduced based on clinical features similar to those of her diagnosed siblings). Other metabolites consistent with the further metabolism of 4-hydroxybutyric acid, including 3-hydroxypropionic acid, 3,4-dihydroxybutyric acid, and glycolic and 4,5-dihydroxyhexanoic acids, were identified in increased amounts in the urine of many patients. Deficiency of SSADH activity was demonstrated in extracts of lymphocytes, lymphoblasts, and/or fibroblasts derived from all patients (except P.S.H.).

**CASE REPORTS (See Table)**

Unless otherwise stated, all pregnancies and deliveries were normal, and children were nondysmorphic with normal somatic growth and no associated movement disorder other than ataxia. Pertinent abnormalities are given.

**A.E.-M.**

A.E.-M. was the third child born to consanguineous (first cousins) Palestinian-Lebanese parents and first cousin to M.H. At 9 years of age in the United States, determined that the patient

**A.F.**

A.F. first presented at 25 years of age. He was born to nonconsanguineous Chinese parents. His early cognitive and language development were normal, with first words at 10 months and full sentences by 2 years of age. His motor milestones were delayed; he did not walk until 2 years of age.

**TABLE. Clinical Findings in 23 Patients With Succinic Semialdehyde Dehydrogenase Deficiency**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age at Diagnosis</th>
<th>Ethnicity</th>
<th>Consanguinity</th>
<th>Neonatal Problems</th>
<th>Normal Early Development</th>
<th>Mental Delay</th>
<th>Motor Delay</th>
<th>Language Delay</th>
<th>Ataxia</th>
<th>Hypotonia</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.E.-M.</td>
<td>M</td>
<td>4 mo</td>
<td>Palestinian-Lebanese</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+†</td>
<td></td>
</tr>
<tr>
<td>A.F.</td>
<td>F</td>
<td>25 y</td>
<td>Chinese</td>
<td>-</td>
<td>-</td>
<td>$§</td>
<td>+†</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
</tr>
<tr>
<td>B.E.</td>
<td>F</td>
<td>5 y</td>
<td>Turkish</td>
<td>-</td>
<td>-</td>
<td>+†‡</td>
<td>+†‡</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
</tr>
<tr>
<td>B.H.</td>
<td>F</td>
<td>19 mo</td>
<td>Syrian</td>
<td>+</td>
<td>-</td>
<td>+‡</td>
<td>+‡</td>
<td>+</td>
<td>+‡</td>
<td>-</td>
<td>+‡</td>
</tr>
<tr>
<td>C.S.</td>
<td>F</td>
<td>10 mo</td>
<td>American</td>
<td>+§</td>
<td>Mild‡</td>
<td>Mild‡</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
</tr>
<tr>
<td>D.E.</td>
<td>M</td>
<td>7 y</td>
<td>German</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
<td></td>
</tr>
<tr>
<td>E.G.</td>
<td>F</td>
<td>8 y</td>
<td>Dutch</td>
<td>+</td>
<td>+‡</td>
<td>+‡</td>
<td>+‡</td>
<td>+‡</td>
<td>+‡</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>I.C.</td>
<td>M</td>
<td>2 y</td>
<td>American-European</td>
<td>-</td>
<td>+§</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+‡</td>
<td>-</td>
<td>+‡</td>
</tr>
<tr>
<td>I.O.</td>
<td>F</td>
<td>11 mo</td>
<td>Turkish</td>
<td>+</td>
<td>+†</td>
<td>+†</td>
<td>+†</td>
<td>+†</td>
<td>+†</td>
<td>+†</td>
<td></td>
</tr>
</tbody>
</table>

* MRI indicates magnetic resonance imaging; and CT, computed tomography.
† First cousins.
‡ Presenting signs.
§ See "Case Reports."
|| Siblings.
†† Siblings.
### TABLE. Clinical Findings in 23 Patients With Succinic Semialdehyde Dehydrogenase Deficiency

<table>
<thead>
<tr>
<th>Patient</th>
<th>Reflexes</th>
<th>Ocular Problems</th>
<th>Behavioral Problems</th>
<th>Hyperkinesis</th>
<th>Psychosis</th>
<th>Seizures</th>
<th>Electroencephalogram</th>
<th>Neuroimaging*</th>
<th>Carnitine Treatment with Vigabatrin</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.E.-M.†</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI normal</td>
<td>Ineffective</td>
</tr>
<tr>
<td>A.F.</td>
<td>Normal</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI normal</td>
<td>Ineffective</td>
</tr>
<tr>
<td>B.E.</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI normal</td>
<td>Ineffective</td>
</tr>
<tr>
<td>B.H.</td>
<td>Absent</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI§</td>
<td>Effective§</td>
</tr>
<tr>
<td>C.S.</td>
<td>Normal</td>
<td>—</td>
<td>+</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+/$§ Abnormal</td>
<td>CT§</td>
<td>Low</td>
</tr>
<tr>
<td>D.E.</td>
<td>Normal</td>
<td>—</td>
<td>+</td>
<td>+</td>
<td>—</td>
<td>—</td>
<td>+/$§ Normal</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>E.G.</td>
<td>Normal</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>I.C.</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>I.O.</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI§ cranial sonogram normal</td>
<td>Low</td>
</tr>
<tr>
<td>J.E.Y.</td>
<td>+</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>J.L.Y.</td>
<td>+</td>
<td>—</td>
<td>+</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>K.S.</td>
<td>Decreased</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Effective§</td>
</tr>
<tr>
<td>M.H.†</td>
<td>Absent§</td>
<td>—</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Ineffective</td>
</tr>
<tr>
<td>M.S.</td>
<td>Normal</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>CT§</td>
<td>Low</td>
</tr>
<tr>
<td>M.W.</td>
<td>Normal</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>CT normal</td>
<td>Low</td>
</tr>
<tr>
<td>N.O.</td>
<td>+</td>
<td>—</td>
<td>Abnormal§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI probably normal?</td>
<td>Effective§</td>
</tr>
<tr>
<td>P.F.</td>
<td>Decreased§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Normal</td>
<td>MRI normal</td>
<td>Very effective</td>
</tr>
<tr>
<td>P.L.</td>
<td>Absent</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>MRI normal</td>
<td>Very effective</td>
</tr>
<tr>
<td>P.S.H.§</td>
<td>Decreased§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+§ Abnormal§</td>
<td>MRI normal</td>
<td>Ineffective§</td>
</tr>
<tr>
<td>P.S.§†</td>
<td>Decreased§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+§ Abnormal§</td>
<td>CT normal</td>
<td>Ineffective§</td>
</tr>
<tr>
<td>P.V.§†</td>
<td>Decreased§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+§ Abnormal§</td>
<td>CT§ MRI normal</td>
<td>Ineffective§</td>
</tr>
<tr>
<td>T.A.</td>
<td>Decreased§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>Abnormal</td>
<td>—</td>
</tr>
<tr>
<td>Y.A.</td>
<td>Normal</td>
<td>+§</td>
<td>+§</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>+§ Abnormal§</td>
<td>Abnormal</td>
<td>—</td>
</tr>
</tbody>
</table>

had minimal brain dysfunction. He was then placed in a special education program. During adolescence he had grand mal seizures but has remained seizure-free while taking carbamazepine (Tegretol) and primidone (Mysoline).

At 22 years of age, after completion of a special education program in the United States, the patient returned to Hong Kong and began to have symptoms of psychosis and hallucinations, which were successfully treated with haloperidol (Haldol). Genetic evaluation at 25 years of age revealed an uncooperative, psychotic, bilingual man with tall stature, macrocephaly, and a long, triangular face. He had a complex partial seizure disorder. Neurologic examination was nonfocal, cranial magnetic resonance imaging (MRI) showed no abnormalities, and the electroencephalographic background was diffusely slow. Vigabatrin therapy was ineffective.

**B.E.**

B.E. was born to nonconsanguineous Turkish parents. His psychomotor development was retarded; she walked at 30 months with an unsteady gait. Developmental tests at 5 years of age placed her at a 15- to 18-month developmental level. Her speech development was poor; her vocabulary consisted of only a few words. Neurologic examination results were normal and did not show ataxia or hypotonia. Alternating strabismus was noted. Vigabatrin therapy, attempted for 2 months without clinical effect, was discontinued.

**B.H.**

B.H., a Syrian boy born to consanguineous parents (cousins), presented at 19 months of age for evaluation of hypotonia since the age of 2 months. He has three siblings who are well and have no developmental problems. The mother received antibiotics and benzodiazepines for leg pain during the fifth and sixth months of pregnancy. The child had a history of recurrent respiratory distress and had three previous hospital admissions for chest infections, one associated with tonic-clonic movements (which may have been related to an aminophylline overdose). Developmentally, he had no formed words at 19 months. Although he was slow to feed, there were no problems with swallowing or vomiting. He had extreme hypotonia with marked head lag, laxity of ligaments, and absent reflexes.

A muscle biopsy revealed nonspecific type 2 atrophy. MRI showed no abnormalities and a minor increase in signal in the white matter posterolateral to the lateral ventricles. After starting vigabatrin therapy, the patient made slow but definite improvement. Of note was the immediate cessation of hospital admissions for respiratory infections. The patient's breathing remained normal, he became more responsive and playful, and his head control improved; however, he remained hypotonic and developmentally delayed. At 2½ years of age, he sat on his own and began to crawl, although his speech consisted of monosyllables. At 3 years of age, he crawled on all four limbs but remained hypotonic and areflexic.

**C.S.**

C.S., an American-European girl, presented for evaluation at 10 months of age. She was born after a pregnancy complicated by hyperemesis gravidarum requiring total parenteral nutrition and preterm labor at 32 weeks' gestation. At 7 months of age, she was admitted to the hospital after an accident in which she sustained...
ments. No pathologic reflexes could be elicited. Ophthalmologic exami-

D.E. presented at 7 years of age. This German boy had the de-

D.E., an 8-year-old Dutch girl, presented with mental retardation

E.G., an 8-year-old Dutch girl, presented with mental retardation

E.G., an 8-year-old Dutch girl, presented with mental retardation

I.C., an American boy born to nonconsanguineous parents of Eu-

I.C., an American boy born to nonconsanguineous parents of Eu-

J.I.Y. presented at 11 months of age for evaluation. She was born to

J.I.Y. presented at 11 months of age for evaluation. She was born to

K.S., a Turkish girl, presented at 2 years of age for evaluation of
delayed development. She has an older sister who is healthy. Develop-
mentally, she sat at 10 months and walked at 20 months. Clinical ex-
amination showed mild muscular hypotonia and hy-

K.S., a Turkish girl, presented at 2 years of age for evaluation of
delayed development. She has an older sister who is healthy. Develop-
mentally, she sat at 10 months and walked at 20 months. Clinical ex-
amination showed mild muscular hypotonia and hy-
In 1992, her cranial MRI showed no abnormalities. In February 1996, symmetric lesions in the globus pallidus, thalamus, and brain stem were identified. The clinical profile has not changed since the last examination.

**M.H.**

M.H., a Saudi Arabian boy (first cousin to A.E.-M.), was born to consanguineous parents (first cousins) and has two older, healthy siblings.

At 3 months, the patient had generalized hypotonia. At 4 months, after hospital admission, he was found to have severe hypotonia and areflexia with poor head control and was unable to raise his head when lying in the prone position. The child seemed alert and interested in his surroundings.

Treatment with vigabatrin began at 9 months of age, and the dose was gradually increased to 100 mg/kg. He made progress while receiving this treatment. Although head control remained poor, the patient almost sat by himself at 10 months of age. At 16 months, he walked with support and spoke a few words, and his deep-tendon reflexes were normal.

**M.S.**

M.S., a 3½-year-old Pakistani girl, presented after a generalized tonic-clonic seizure associated with fever. During the subsequent 24 hours the patient seemed confused and frightened, suggesting encephalopathy. During the next 48 hours, she showed gradual improvement but was then noted to have an unsteady, wide-based gait and a tendency to fall. There were also associated choreiform movements. The patient continued to improve during the ensuing 4 days.

As an infant, she was a weak and poor feeder. Her development was delayed; she sat unaided at 10 months, rolled at 11 months, and began to speak at 20 months. Previous neurologic evaluation failed to reveal a cause.

Reexamination revealed a marked general intellectual delay. Her gait was immature and wide based with normal tone and reflexes. The patient had a depigmented patch on her left abdomen. CT showed generous subarachnoid spaces around the base of the brain, and the fourth ventricle was large. Her EEG was normal.

At examination at 4 years 8 months, the patient still had delay in her psychomotor development. She was able to string two to three words together in both English and her native tongue. Her play was immature, reflective of a child 18 months to 2 years of age. The patient was not toilet trained. She was generally hypotonic with preserved reflexes. She had frequent involuntary movements, predominantly of the upper limbs.

At 7½ years the patient had good situational understanding and was speaking in simple sentences but was still clumsy. Before initiating vigabatrin therapy, the patient had hallucinations, which were primarily visual. These stopped when she began treatment. With continued treatment, her ataxia also improved.

**M.W.**

M.W. presented at 4½ years with significant hypotonia, speech delay, motor delay, and moderate mental retardation. His nonconsanguineous parents were of European ancestry. During early infancy, the patient had problems with vomiting associated with feeding. The patient underwent surgical correction of pyloric stenosis at 8 weeks of age. Frequent episodes of otitis media required antibiotic therapy. She also had frequent episodes of tonsillitis and underwent a tonsillectomy and adenoidectomy at 4 years of age. At 4½ years, he had significant hypotonia, speech delay, motor delay, and moderate mental retardation.

The patient had generalized hypotonia at 4 months, and his motor development was significantly delayed; he sat at 10 months, pulled to stand at 14 months, and walked at 21 months. At 2½ years the patient was referred to a neurologist, who confirmed marked generalized hypotonia without definitive diagnosis. An EEG, electromyography (EMG), and CT of the head were normal. He had an 18- to 20-word vocabulary but was unable to combine words to form sentences. Developmental testing at 2½ years of age determined the patient’s gross-motor skills to be at the 15-month level, fine-motor skills to be at the 12-month level, receptive language skills to be at the 10- to 12-month level, expressive language skills to be at the 12- to 14-month level, and overall cognition to be at the 12-month level.

Evaluation at 4½ years revealed that the child was not toilet trained and was just learning to run. He was unable to dress himself and was unable to use utensils to feed himself, although he could finger feed. Speech and language development also were delayed significantly. He had a 100-word vocabulary and could combine them into two- and three-word sentences. Examination was significant for generalized hypotonia and laxity of joints, with overall decreased muscle tone but intact deep-tendon reflexes. A short (proximal) phalanx on the fifth digit of the right hand was also noted.

The patient’s plasma showed a deficiency of carnitine, with a total carnitine level of 24 nmol/mL (normal, 35 to 50 nmol/mL), a free carnitine level of 20 nmol/mL (normal, 30 to 45 nmol/mL), and a short-chain acylcarnitine level of 4 nmol/mL (normal, 2 to 6 nmol/mL). After treatment with L-carnitine at 30 mg/kg per day, the patient’s muscle tone improved dramatically. His speech and articulation also improved. Results of a subsequent analysis of plasma carnitine levels were within the normal range. Another examination after 2 months of L-carnitine therapy showed essentially normal muscle tone and strength.

**N.O.**

N.O. was born to nonconsanguineous Bulgarian parents. He began walking at 12 months and began speaking at 2 years of age, although he never exceeded three-word sentences. His motor development was normal, except for problems with small motor function and slight ataxia. He was hyperkinetic and was unable to concentrate for more than 10 minutes. He did not sleep through nights and often ground his teeth during sleep.

At 12 years of age, school entrance testing with nonverbal test material revealed a mental development age of 3½ years. His ability to communicate was severely hampered by his language disabilities, which included stuttering, repetitions, and a minimal vocabulary. Later in his development, he was able to understand both German and Bulgarian. He was hyperactive and had some minor fine-motor deficits, which occasionally were noticeable. The EEG was irregular and slow, and MRI showed only a few nonspecific hyperintensive signals in the area of the left globus pallidus. High doses of vigabatrin improved the patient’s condition but induced electroencephalographic changes and seizures. Lower doses were better tolerated. A report of vigabatrin therapy in this patient is presented elsewhere.

**P.F.**

P.F. was born in Greenland and is ethnically Inuit. Her psychomotor development generally was retarded; she walked at 2½ years of age. At 4 years of age, she ran, spoke three- to four-word sentences, and understood what was said to her. Her muscle tone was slightly decreased, and she had weak reflexes. Her eye examination revealed mild strabismus.

**P.L.**

P.L. was the male child of nonconsanguineous American parents of European heritage. At 4 months of age, lethargy developed, which was associated with emesis, hypotonia, and a distended bladder.

At examination, his weight was in the 5th percentile, height was in the 10th percentile, and head circumference was in the 60th percentile. He was thin and pale, with a marked absence of subcutaneous fat. Motor examination revealed marked truncal and appendicular hypotonia; however, no atrophy or fasciculations were identified. After the diagnosis of SSADH deficiency, vigabatrin therapy was started.

At 5 years of age, she had received 75 mg/kg vigabatrin for more than 24 months with no side effects. There was little progress in mental development; her developmental level was approximately that of a 2-year-old. She spoke only a few German words and some short sentences in Turkish. Her physical progress was poor, and she had extreme hypotonia, although she was able to walk and run slowly.

The clinical profile has not changed since the last examination.
for evaluation. During her first few months, she reportedly had no improvement in intellectual ability or behavior. Treatment was thereby discontinued because of disturbing hyperalimentation and increasing sleepiness during the day.

P.S. (Note: Diagnosis Deduced After Death Because of Two Affected Siblings)

P.S. was the firstborn child to a nonconsanguineous Indian couple. The mother had a slight build and a somewhat unstable, atactic gait. At 9 months, P.S. had poor head control and general muscular hypotonia. At 11 months, the child sat alone but had poor reflexes. The EEGs revealed multifocal discharges.

The patient began having absence seizures at 2 years of age. Psychomotor development was severely delayed; the child stood alone at 18 months of age, walked alone at 21/2 years of age, and spoke only one or two words by 3 years of age. The parents reported that the child was restless, had difficulty concentrating, and often missed objects when attempting to grab them.

Examination and clinical studies revealed no neurodevelopmental or metabolic disorders. Treatment with valproic acid resulted in increased alertness and balance, and seizures became less frequent and finally ceased. The valproic acid treatment was discontinued at 10 years of age after 5 seizure-free years. Approximately 1 year later, generalized epileptic seizures recurred and continued with increased frequency. The child rapidly lost all psychomotor abilities and died at 131/2 years of age.

T.A.

T.A. was born after a pregnancy complicated by spotting at 5 months and treated with bedrest. The mother also had a 11/2-pack-per-day smoking habit. The consanguineous (first cousins) Lebanese parents had two other children, a 16-year-old and a 14-year-old, who were healthy.

As an infant, the patient had trismus and periodic episodes of stiffening, with his head turning to the left and possible back arching. His motor development was delayed; he sat alone at 11/2 years, crawled alone at 4 years, walked alone at 4 years, and could not climb stairs on his own. He had poor fine-motor ability with marked faciomyelitis, general muscular hypotonia, and hyporeflexia.

The EEG had an abnormal background rhythm and continuous β activity with generalized, irregular spike wave discharges. In addition, multifocal discharges, with separate foci seen over both hemispheres, were enhanced by intense photic stimulation. Diagnosis was made because of sibling P.V.

MRI of her brain revealed no abnormalities at 10% years of age. Menarche was at 11% years of age. At 13% years, her physical development was normal, and her height and weight were in the 25th percentile. There was no further intellectual development, and she was not able to speak, with the exception of a few incoherent syllable duplications. She was still unable to follow simple commands, which primarily was because of her severe hyperactivity and limited attention span. She attended a special school for severely retarded children. Her ataxia has not progressed, although she has a wide-based gait. There was no more seizure activity with the increased dosage of valproic acid (40 mg/kg per day) beginning September 1994. The EEG has a slightly abnormal background activity but no more discharges and no pathologic reaction to photic stimulation. The initial dosage of vigabatrin was 20 mg/kg per day and was increased during a period of 11/2 years to 40 mg/kg per day. During this time, there was no improvement in intellectual ability or behavior. Treatment was discontinued because of disturbing hyperalimentation and increasing sleepiness during the day.

P.V.

P.V. presented at 3 years of age. The female sibling of patients P.S. and P.S.H., she was born prematurely at 29 weeks after an uneventful pregnancy. During early infancy, feeding problems developed that have continued to the present. Psychomotor development was notably delayed; she sat alone by 12 months but could not stand alone by 3 years of age. The patient was unable to speak at 3 years of age; however, she reacted to sound and seemed to understand but was unable to follow simple directions. Absence seizures developed at 21/2 years of age.

Physical examination revealed her weight at the 25th percentile, height at the 25th percentile, and head circumference below the 3rd percentile. She had general muscular hypotonia, faciomyelitis, and hyporeflexia. The EEG showed an abnormal background rhythm with bilateral, irregular, multifocal spike wave discharges. In addition, sharp, slow-wave foci were seen over the left hemisphere. In general, there was no change in the EEG and discharge patterns during the next 41/2 years. At 6 years of age, CT of the head revealed no abnormalities.

At reevaluation at the age of 71/2 years, she was microcephalic (<3rd percentile), and her height and weight were in the 25th and 3rd percentiles, respectively. She could hear but had no speech development. She was unable to follow simple commands. She had minimal motor development improvement; although she crawled well and pulled to stand, she could not stand or walk alone. Restlessness and hyperactivity developed, which limited her concentration. She attended a special school for severely retarded children. She has had no grand mal seizures but has had frequent (daily) absence seizures and myoclonic absence seizures. The seizure frequency could be reduced by treatment with valproic acid and ethosuximide. Vigabatrin treatment has not been attempted.

P.S., the younger female sibling of P.S.H., presented at 9% years for evaluation. During her first few months, she reportedly had delayed motor development, poor head control, and general muscular hypotonia. She sat alone at 12 months, stood at 18 months, and walked at 30 months.

She began having absence seizures at 4% years of age; phenobarbital briefly reduced the frequency of the seizures. Grand mal seizures started when the patient was 7 years old and were treated with valproic acid.

At examination, the patient was friendly and alert and tried to follow simple directions, but she was restless and unable to concentrate. She spoke only one or two words. The patient's skeletal age was retarded. A normal chromosomal analysis was obtained. Her height and weight were in the 25th percentile. She had general muscular hypotonia, decreased muscle strength, and hyporeflexia. His speech was unclear, and he spoke in very short sentences. Developmental testing revealed mild to moderate mental retardation.

Y.A.

Y.A. was born to consanguineous Turkish parents. His psychomotor development was delayed; he sat at 12 months, stood at 14 months, and walked alone at 25 months. Speech development also was delayed, with his first words at 3 years. Developmental testing revealed severe retardation.
Neurologic examination revealed convergent strabismus, generalized hypotonia without ataxia, and normal deep-tendon reflexes. CT of the brain and an EMG showed no abnormalities.

He had multiple episodes of clouded consciousness, shouting, and abnormal behavior occurring between the ages of 2 and 3½ years. These episodes generally occurred with fever and were 10 to 15 minutes in duration. His EEG revealed hypofunctional abnormalities, especially posteriorly; however, no epileptic abnormalities were found.

Vigabatrin therapy (50 mg/kg) was initiated at 27 months of age and was increased to 100 mg/kg at 37 months of age. There have been no clear clinical effects of the vigabatrin.

**DISCUSSION**

The presenting problem varied among the patients studied; however, in general, the presenting symptoms were neurologic (Table). The following presenting signs were observed: motor delay, 14 patients; hypotonia, 10 patients; mental delay, 9 patients; language delay, 6 patients; ataxia, 3 patients; seizures, 2 patients; and neonatal problems, 1 patient. All of the patients presented with one (or more) of these symptoms for which the parents sought help. The Table verifies the wide range of phenotypic presentation. Even in sibships, the disease presentation is not completely consistent. For example, J.I.Y. had hyperkinesia, which was not observed in the younger sibling, whereas the younger sibling, J.E.Y., had evidence of hypotonia not seen in her older sibling. In a sibship of three patients, however, the phenotype was very consistent. The lack of a clear-cut presenting phenotype and the significant variability in overall presentation further underscores the variable nature of SSADH deficiency and the relative likelihood that the disorder is frequently undiagnosed or even misdiagnosed.

In our patients, we tabulated the following descendents: Turkish, 4; white American, 4; Northern European (German, Dutch, and Bulgarian), 3; Indian, 3; Palestinian (Lebanese), 2; Korean, 2; Syrian 1; Saudi, 1; Inuit (Greenland), 1; Pakistani 1; and Chinese, 1. To date, we know of no patients detected with SSADH deficiency who are in South America or Africa. One of the first patients in whom SSADH deficiency was diagnosed was thought to have originated from Algeria, but it is unclear whether he was French or Algerian by birth. Thus, SSADH deficiency seems to be primarily a disorder of the Eurasian region. Whether a founder effect can be linked to the disease remains to be determined. On the other hand, this may simply reflect more efficient metabolic screening of the pediatric population for inherited disease in the Northern European region. Approximately 40% of the probands in this report are offspring of consanguineous parents, a very high incidence of consanguinity. This may account for a Middle Eastern predominance in the geographic distribution of patients because of cultural habits. On the other hand, it may imply that disease-related alleles are rare in the human population. A high incidence of consanguinity is also consistent with multiple loci, but this will be addressed through molecular genetic studies.

At this time, it is difficult to assess whether “distinct” or “variant” forms of SSADH deficiency disease exist, because the patient population is still too small. The SSADH gene is single copy and has been mapped to chromosome 6p23. However, until we have determined through molecular analysis that the disease maps to this locus in each patient, it remains preferable to refer to variant forms of SSADH deficiency. We do not know whether modifier loci have a role, and it remains possible that heterogeneity may be more than allelic.

One intriguing finding in the tabulation of our patients is the possible distinction of early- and late-onset forms of SSADH deficiency, or at least forms of the disease differentiated by development during infancy. Remarkably, the Table verifies that 7 of 23 patients had normal early development. This is not to say that the ensuing clinical course in these putative “late-onset” patients is mild. Moreover, it is difficult to identify any one factor as the cause of the late-onset disease form. Molecular genetic analyses eventually may provide answers to these questions. Another interesting observation is the fact that therapeutic intervention with the GABA transaminase inhibitor vigabatrin was only clinically beneficial in about one third of patients (Table).

The lack of therapeutic efficacy with vigabatrin is of interest. Therapeutic efficacy may again reflect heterogeneity at the genetic or enzymic level. On the other hand, Howells and colleagues have suggested that vigabatrin has limited use in SSADH deficiency because of differential effects on organ specific GABA transaminases. These investigators postulated that although vigabatrin may inhibit brain GABA transaminase effectively, limited inhibition of peripheral organ GABA transaminases could lead to resupply of 4-hydroxybutyric acid across the blood-brain barrier, thereby decreasing the clinical efficacy of therapeutic intervention in the central nervous system.

Intervention with high-dose vigabatrin actually had deleterious effects in one patient. Accordingly, Matern and colleagues found that titrating the vigabatrin dose to a clinically beneficial level was prudent in their patient with SSADH deficiency. High levels of vigabatrin (75 to 100 mg/kg per day) induced electroencephalographic abnormalities and seizure activity in this patient, whereas lower levels (25 mg/kg per day) were beneficial. For future reference, physicians treating patients with SSADH deficiency may wish to administer vigabatrin in increasing quantities. Interestingly, in the three patients for whom l-carnitine levels were evaluated, the plasma levels were low (Table), and carnitine therapy in M.W. dramatically improved muscle tone. Therefore, l-carnitine intervention should be considered in SSADH deficiency if plasma carnitine levels are low.

This review of 23 new SSADH-deficient patients clearly demonstrates that the clinical phenotype is extremely nonspecific, which suggests that the disorder is significantly underdiagnosed. It is likely that all patients with SSADH deficiency will manifest some degree of psychomotor deficit within their childhood years; however, speech and language delay and hypotonia are not necessary concomitants of the disorder, as previously thought. Although the
findings varied, delayed psychomotor and language development and hypotonia were observed in approximately three fourths of the patients. Notable exceptions were I.C. and A.F. (the latter an adult patient who attended primary school), both of whom had normal development of speech and language. The detection of seizures in half of the patients was surprising, because seizures were not previously thought to be prevalent in SSADH deficiency. On the other hand, the detection of ataxia in only one third of patients was surprising, because ataxia was previously thought to be common in SSADH deficiency. The inability to diagnose SSADH deficiency is exemplified in A.F., in whom the correct diagnosis was not achieved until 25 years of age. Interestingly, this man represents only the second adult patient in whom SSADH deficiency has been diagnosed.

In addition to a nonspecific clinical presentation, other features of SSADH deficiency may often confound the correct differential diagnosis. Patients with SSADH deficiency do not present with the usual concomitants of an inborn error of metabolism. There is no metabolic acidosis, hyperammonemia, hypoglycemia, growth retardation, or episodic decompensation with vomiting and/or lethargy often seen in other inborn errors of metabolism. In addition, the characteristic metabolite in the disorder, 4-hydroxybutyric acid, can elude accurate quantitation because of its ability to lactonize and volatilize. The essential feature for diagnosis of SSADH deficiency is 4-hydroxybutyric aciduria. However, there has not been 100% concordance between metabolite excretion and enzyme deficiency thus far, although the percentage is very high. We are aware of at least two patients who have excreted small amounts of 4-hydroxybutyric acid with normal SSADH activity. These patients must be followed to assess whether metabolite excretion persists. To avoid loss of 4-hydroxybutyric acid after routine acid extraction of urine, clinical laboratories should use extreme caution in removal of solvent. We have found it worthwhile to alkalize acidic extracts of urine to at least pH 5 after acidic extraction to avoid substantial loss of 4-hydroxybutyric acid. Moreover, gas chromatographic analysis alone is insufficient to detect small elevations in urine; mass spectrometric analysis is essential for correct diagnosis. We and others use isotope-dilution methods for metabolite quantification in physiologic fluids from patients with 4-hydroxybutyric aciduria, which is the most accurate approach for quantita-

Several specialist laboratories have considerable expertise in accurately diagnosing SSADH deficiency through organic acid analysis. Our recommendation would be that accurate, quantitative, urine organic acid analysis be requested for any patient presenting with two or more features of mental, motor, or language delay and hypotonia of unknown cause. Such analyses are the only definitive way to diagnose SSADH deficiency; the diagnosis can be confirmed by determination of enzyme activity in white cells from whole blood. We think that increased use of organic acid analysis will lead to increased diagnosis of SSADH deficiency, which will result in a more accurate representation of the disease frequency. As additional patients are identified, we should have a better understanding of both the metabolic and clinical profile of SSADH deficiency.

ACKNOWLEDGMENTS

This work was supported in part by the Gamma Hydroxybutyrate Research Fund, Baylor University Medical Center and Baylor Health Care System, Dallas, TX. We are indebted to Rebecca Atnip for editing the manuscript, Dr G. Mues for assistance in translation of patient histories, and Dr M. I. Gibson for assistance in the construction of case reports, tabular formatting, and critical evaluation of the manuscript.

REFERENCES


